Fundsmith 13F: Cuts Medpace (MEDP) Stake by $11M

Fundsmith scaled back its investment in Medpace Holdings, Inc. (NASDAQ: MEDP) by 24.1% during the period ending May 15, 2026, according to its latest Form 13F filing with the Securities and Exchange Commission. The fund sold 19,899 shares of the company, leaving it with 62,668 shares. The remaining stake was valued at approximately $33.19 million at the time of the filing.

Trimming the Stake

Before this reduction, Fundsmith held 82,567 shares of the clinical research firm. The fund's cost basis for the position was $336.26 per share. The 24.1% decrease in holdings follows a pattern of recent trims by Fundsmith, which has also reduced positions in other mid-cap healthcare and technology names. Because 13F filings are backward-looking documents, they show a snapshot of holdings on the filing date and may not reflect the fund's current active portfolio today.

Medpace Stock Performance

On Saturday, Medpace shares were priced at $529.59. Since Fundsmith disclosed its stock sale on May 15, 2026, the stock has faced some downward pressure. The current price sits just above the company's 200-day moving average of $525.63, but it has fallen below its 50-day moving average of $604.91. Over the last 52 weeks, Medpace has traded in a wide range, hitting a low of $373.00 and reaching a high of $677.90.

Recent Earnings

Medpace reported annual revenue of $2.78 billion, representing a revenue growth rate of 17.2%. The company has maintained a healthy net margin of 17.67% and a strong return on equity of 162.15%. Medpace reported diluted earnings per share of $17.03. Investors are keeping a close eye on the company's next earnings report, which is scheduled for release on October 21, 2026.

Analysts Set New Price Targets

Wall Street analysts have issued mixed opinions on the stock in recent months. On October 7, 2026, Mizuho maintained an Outperform rating and set a price target of $700.00. That same day, Barclays maintained an Equal-Weight rating with a price target of $625.00. Earlier, on September 30, 2026, UBS upgraded the stock to a Neutral rating with a price target of $673.00. BMO Capital holds a Market Perform rating with a target of $600.00, while TD Cowen has a Hold rating with a lower target of $492.00. Overall, the consensus target price among 13 analysts is $595.92, with a general recommendation key of hold.

About Medpace Holdings

Medpace operates as a clinical contract research organization. The company helps biotech, pharmaceutical, and medical device companies design and run their clinical trials from Phase I to Phase IV. This service includes everything from central laboratory services to project management and data analysis. As biotech funding fluctuated throughout the year, Medpace's steady pipeline of clinical trial management has remained a key focus for institutional investors like Fundsmith.

What's Ahead for Medpace Holdings, Inc.

Market observers will want to watch whether Medpace can maintain its revenue growth in its upcoming quarterly report on October 21, 2026. Future SEC filings from Fundsmith and other institutional investors will also reveal whether large funds continue to pare down their holdings or if they begin buying back into the clinical trial sector at these lower price levels.